| 吴共国,邓清华,杨建锋,等.吉非替尼与多西他赛治疗晚期非小细胞肺腺癌的疗效观察[J].中国临床保健杂志,2019,22(3):406-408. |
| 吉非替尼与多西他赛治疗晚期非小细胞肺腺癌的疗效观察 |
| The therapeutic effects of gefitinib and docetaxel on advanced non-small cell lung adenocarcinoma |
| 投稿时间：2018-12-20 |
| DOI：10.3969/J.issn.1672-6790.2019.03.031 |
| 中文关键词: 癌,非小细胞肺 吉非替尼 多西他赛 治疗结果 |
| 英文关键词: Carcinoma,non-small-cell lung Gefitinib Docetaxel Treatment outcome 〖FL |
| 基金项目:浙江省医药卫生科技计划项目(2019ZD017)；浙江省杭州市卫生科技重大项目(20120533201) |
|
| 摘要点击次数: 5857 |
| 全文下载次数: 4427 |
| 中文摘要: |
| 目的 探讨吉非替尼与多西他赛治疗晚期非小细胞肺腺癌的临床疗效。方法 选取100例晚期非小细胞肺腺癌患者,采用随机数字表法分为吉非替尼组(50例,口服吉非替尼治疗,250毫克/次,1次/天)与多西他赛组(50例,静脉滴注多西他赛治疗)。比较两组患者的临床疗效、肿瘤生命质量核心问卷(QLQ-C30)评估结果以及副作用发生情况。结果 吉非替尼组的局部控制率与总有效率(44.0%、68.0%)均高于多西他赛组(20.0%、54.0%),P均<0.05。吉非替尼组患者治疗后QLQ-C30问卷的整体功能评分高于多西他赛组,且特异症状评分低于多西他赛组P<0.05。吉非替尼组患者治疗后的肌酸激酶同工酶水平低于多西他赛组(P<0.05)。吉非替尼组的副作用发生率(14.0%)略低于多西他赛组(16.0%),差异无统计学意义(P>0.05)。结论 吉非替尼与多西他赛治疗晚期非小细胞肺腺癌均具有一定的疗效,但吉非替尼优于多西他赛。 |
| 英文摘要: |
| Objective To observe the efficacy of gefitinib and docetaxel in the treatment of advanced non-small cell lung adenocarcinoma.Methods 100 patients with advanced non-small cell lung adenocarcinoma were randomly divided into gefitinib group (50 cases,oral gefitinib treatment) and docetaxel group (50 cases,intravenous drip of docetaxel treatment).The clinical efficacy,QLQ-C30,myocardial function (creatine kinase isozyme,ejection fraction) and side effects (leucopenia,rash,vomiting,diarrhea and elevated amino transferase) were compared between the two groups.Results The local control rate and total effective rate (44.0% and 68.0%) of gefitinib group were higher than those of docetaxel group (20.0% and 54.0%,respectively),P<0.05.The overall functional score of QLQ-C30 questionnaire in gefitinib group was higher than that in docetaxel group,and the score of specific symptoms was lower than that in docetaxel group (P<0.05).The level of creatine kinase isoenzymes in gefitinib group was lower than that in docetaxel group (P<0.05).The incidence of side effects in gefitinib group (14.0%) was slightly lower than that in docetaxel group (16.0%) with no significant difference (P>0.05).Conclusions Both gefitinib and docetaxel are effective in the treatment of advanced non-small cell lung adenocarcinoma.Gefitinib is superior to docetaxel. |
|
查看全文
|
| 关闭 |
|
|
|